Cencora, Inc. (NYSE:COR – Get Free Report) has received an average recommendation of “Moderate Buy” from the ten analysts that are presently covering the firm, Marketbeat.com reports.

It has been about a month since the last earnings report for Cencora (COR). Shares have added about 3.1% in that time frame, outperforming the S&P 500. Will the recent positive trend continue ...

We note that Cencora, Inc. (NYSE:COR) does have debt on its balance sheet. But the real question is whether this debt is making the company risky. Debt is a tool to help businesses grow ...

Fisher Asset Management LLC boosted its stake in shares of Cencora, Inc. (NYSE:COR – Free Report) by 17.7% during the 4th quarter, according to its most recent 13F filing with the SEC.

Argus analyst David Toung raised the firm’s price target on Cencora (COR) to $280 from $270 and keeps a Buy rating on the shares. The company delivered strong results for Q1 and expects topline ...

Cencora, formerly known as AmerisourceBergen, is one of the Big 3 drug distributors alongside peers McKesson Corporation (MCK) and Cardinal Health, Inc. (CAH). It provides pharmaceutical ...

Cencora has a solid industry position in an oligopolistic market with supernormal return ratios and solid stock price returns. 1QFY25 results, as well as the near-term outlook, are also solid ...

Cencora COR has outperformed the market over the past 5 years by 8.2% on an annualized basis producing an average annual return of 20.8%. Currently, Cencora has a market capitalization of $47.04 ...

Headquartered in Conshohocken, Pennsylvania, Cencora, Inc. (COR) is a leading pharmaceutical services company dedicated to enhancing global healthcare. With a market cap of $47.7 billion ...